Company Information

Location

San Diego, USA

CEO

Ciara Kennedy, PhD

Amplyx was founded with the mission to develop innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems. Amplyx is advancing development programs with the potential to protect these vulnerable patients, including those with cancer and transplants, and the critically ill.

The company’s two lead products are fosmanogepix (APX001) for the treatment of life-threatening fungal infections caused by pathogens such as Candida, Aspergillus and rare molds; and MAU868, a monoclonal antibody designed to neutralize the BK virus which can cause significant morbidity and mortality in transplant patients.

Amplyx was acquired by Pfizer in April 2021